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To evaluate the prevalence of off-label and unlicensed prescribing in inpatients at a major
paediatric teaching hospital in Western Australia and to identify which drugs are commonly
prescribed off-label or unlicensed, including factors influencing such prescribing.
Methods
A retrospective cross-sectional study was conducted in June, 2013. Patient and prescribing
data were collected from 190 inpatient medication chart records which had been randomly
selected from all admissions during the second week of February 2013. Drugs were catego-
rised as licensed, off-label or unlicensed, according to their approved Australian registration
product information (PI). All drugs were classified according to the Anatomical Therapeutic
Chemical (ATC) code.
Results
There were 120 male and 70 female inpatients. The average age was 6.0 years (± 4.7). The
study included 1160 prescribed drugs suitable for analysis. The number of drugs prescribed
per patient ranged from 1 to 25 with an average of 6.1 (± 4.3). More than half (54%) were
prescribed off-label. Oxycodone, clonidine, parecoxib and midazolam were always pre-
scribed off-label. The most common off-label drugs were ondansetron (18.5%), fentanyl
(12.9%), oxycodone (8.8%) and paracetamol (6.1%). Many ATC classifications included
high off-label proportions especially the genitourinary system and sex hormones, respiratory
system drugs, systemic hormonal preparations and alimentary tract and metabolism drugs.
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Conclusions
This study highlights that prescribing of paediatric drugs needs to be better supported by
existing and new evidence. Incentives should be established to foster the conduct of evi-
dence-based studies in the paediatric population. The current level of off-label prescribing
raises issues of unexpected toxicity and adverse drug effects in children that are in some
cases severely ill.
Introduction
Registration of medications in Australia requires assurances of efficacy, quality and safety. The
Therapeutic Goods Administration (TGA) is responsible for the licensing and labelling con-
tent of medications for use within Australia [1, 2]. However, despite this process medications
are often used in either an off-label and occasionally unlicensed manner. Off-label prescribing
refers to the use of a drug in a manner different from that for which it is registered [3, 4]. This
includes being utilised in the treatment of a different indication, at a different dose or dosage
frequency, via a different route of administration and also when it is prescribed for a different
age and/or weight to that stated in the registered product information [3, 4]. Unlicensed pre-
scribing includes instances when drugs are prescribed but they have not been licenced for use
by the TGA [4, 5]. Modification or reformulation of a licensed drug is also classified as unli-
censed prescribing [1, 4, 5].
This practice is highlighted in the prescribing of medications for children. The quantity and
range of drugs currently licensed and labelled for use in children is limited and therefore pre-
scribers may resort to off-label or unlicensed use out of perceived clinical necessity. Ethical
concerns may limit clinical trials being performed in children leading to a lack of paediatric
registration [6]. Such prescribing presents a number of safety concerns. The pharmacokinetics
and pharmacodynamics of drugs can be significantly affected by age [6]. In paediatric patients,
the two main drug metabolising enzyme systems are the phase I and phase II reactions, which
are often different to adults. Phase I reactions, which usually convert the parent drug to a more
polar metabolite, involve cytochrome P450 enzymes of which CYP3A4 is the most important
and is involved in the metabolism of many drugs including carbamazepine, erythromycin, fen-
tanyl, ketoconazole and nifedipine. The activity of CYP3A4 is very low in neonates, increases
in the first 12 months of life and is higher in infants and children than in adolescents and
adults. Glucuronidation, a phase II reaction, also varies with age and is reduced in neonates
but increases in infants and children. Drugs that undergo predominantly glucuronidation
include paracetamol and morphine [7]. The variation in drug metabolism parameters within
different age groups highlights the importance of further investigation and consideration for
paediatric prescribing [8]. Extrapolation of adult dosing schedules to children may be inappro-
priate and lead to poor efficacy or adverse effects.
Off-label and unlicensed prescribing is a common occurrence in children’s hospitals glob-
ally [9–12]. Past studies conducted in Australia have also found that off-label prescribing is a
common occurrence in hospitals. A Tasmanian study involving 300 patients aged� 12 years
reported that 31.8% of drugs prescribed in a paediatric ward of a teaching hospital were off-
label and that 2 of the 5 reported adverse drug reactions involved drugs used in an off-label
manner [2]. It was concluded that the prescribing of medicines off-label was often supported
by available evidence and indicated that there was a need for Australian paediatric prescribing
guidelines [2].
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A study at a major paediatric teaching hospital in Western Australia in 2008 involving inpa-
tients, Emergency Department patients and outpatients� 18 years [1] reported that the clini-
cal setting influenced the level of off-label prescribing. The highest proportions of patients who
were prescribed at least one off-label drug were inpatient children aged two to 11 years (85%)
and neonates aged zero to 27 days (83%). Overall, the ten most frequently prescribed off-label
drugs were ondansetron (13.8%), Painstop Day (10%), salbutamol (7.5%), oxycodone (7.2%),
paracetamol (7.1%), midazolam (4.3%), fentanyl (3.1%), Timentin (ticarcillin with clavulanic
acid) (2.8%), amoxicillin (2.6%) and flucloxacilin (2.6%).
Since off label or unlicensed prescribing has the potential to be detrimental to patients it is
necessary to identify areas of current prescribing practice where this is occurring and to iden-
tify its prevalence. In addition, it shows where drug registration data are needed to be
expanded by sponsors.
The principal aim of this study was to investigate the prevalence of off-label and unlicensed
prescribing for inpatients at Princess Margaret Hospital (PMH). The study also investigated
major causative factors behind this practice and aimed to determine if there was any associa-
tion between off-label and unlicensed prescribing practices and demographic or diagnostic
data.
Methods
A retrospective cross-sectional study was conducted on inpatients at PMH, a 220 bed tertiary
teaching paediatric hospital in Western Australia. Data were collected in June, 2013. The study
randomly selected (using a web-based program) 215 medication chart records from 595 inpa-
tient cases for the second week of February, 2013. Each record was given a unique re-identifi-
able code, held by the Chief Pharmacist at PMH. Data collected included date of birth, sex,
weight, height (when available), presenting complaint, diagnosis, known allergies, and a full
medication profile for each subject. The medication profile included the drug, dose, frequency,
indication and route of administration. Drugs were given a separate listing if the same drug
was prescribed at a different dose or for a different indication. Also, if the drug was given via
more than one route, and the different route resulted in a different classification, the drug was
then given two separate listings for ease of analysis. All data were entered into Microsoft Excel.
Of the 215 randomly selected medication charts, six were excluded as the indications in one
chart were unclear and for five oncology patients, access to their files was limited at the time of
data collection. Other exclusions were medications charts from patients on psychiatric drugs
as these were unable to be accessed, incomplete medication charts or medication charts not
able to be located at the Patient Information Management Services (PIMS), where the records
were held.
Drug exclusions included any gases and inhalations used during surgery such as nitrous
oxide and sevoflurane; propofol; blood products; intravenous fluid drips or pushes; oxygen
therapy; and any medications given in the Emergency Department.
Following data collection, each prescribed drug was classified as licensed, off-label or unli-
censed by consulting the Product Information (PI) from the Therapeutic Goods Administra-
tion website [13] and the 2013 eMIMS [14]. The drug was listed as off label if any of the
following applied:
1. Dosage: Doses within 10% of the value specified in the PI were considered licensed. This
allowed for rounding, and was done to reduce the chance of over estimating the prevalence
of off-label use. Doses outside this range (>±10%) were listed as high or low compared to
the PI, based on age or weight.
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2. Age/ weight: The PI stated that the drug was not approved or recommended for use in chil-
dren under a specific weight or age.
3. Indication: The PI stated that the drug was indicated for a condition different to the
diagnosis.
4. Route: The drug was administered via a route not listed in the PI.
Drugs were classified as unlicensed if they were reformulated, not registered with the TGA,
prepared extemporaneously or obtained through the Special Access Scheme (SAS). Under the
SAS, if a patient requires access to therapeutic goods that are not listed on the Australian Regis-
ter of Therapeutic Goods (ARTG), unapproved therapeutic goods may be imported and/ or
supplied for a single patient.
Each drug was classified according to the Anatomical Therapeutic Chemical (ATC) code
[15].
The age of each subject was classified according to the European Medicines Agency (EMA)
classification system which defines neonates as zero to 27 days, infants as 28 days to 23
months, children as two to eleven years, adolescents as 12 to 18 years, and adults as eighteen
years and over [16].
Ethics approval was granted by Curtin University Human Research Ethics Committee
(Approval number PH-13-13) and Princess Margaret Hospital.
Statistical analyses
Simple descriptive statistics (frequencies and percentages for categorical variables, means and
standard deviations for continuous variables) were used to summarise patient demographic
data, and the drugs they were prescribed. Comparisons of the age profile, and the route of
administration of the drugs between drugs listed as off-label and unlicensed was performed
using Chi-square statistics. Analyses were performed using the SPSS version 20 statistical soft-
ware. A p-value < 0.05 was taken to indicate a statistically significant association.
Results
The study evaluated 190 paediatric inpatients of which 120 (63.2%) were male and 70 (36.8%)
were female. The average patient age was 6.0 years (± 4.7). Patient weight ranged from 2.0 to
73.0 kg, the average weight was 26.3 kg and the median was 18.8 kg. There were 1160 pre-
scribed drugs suitable for analysis, of which 44.5% (n = 516) were licensed, 54.0% (n = 626)
were off-label and 1.6% (n = 18) were unlicensed. The number of drugs prescribed per patient
ranged from 1 to 25 with an average of 6.1 (± 4.3).
The most common reasons for off-label prescribing were indication and age (Table 1).
With respect to off-label classification regarding dosage, higher doses occurred almost twice as
often as lower doses (Table 1). Frequently drugs were classified as off-label for more than one
reason. This is demonstrated by a cumulative off-label frequency percentage of 137% of all the
drugs classified as off-label (Table 1). The majority of unlicensed medications were extempora-
neous preparations (55.6%) or reformulations (38.9%). Prescribing through the SAS was rare
(Table 1).
Drugs commonly used off-label included ondansetron, fentanyl, oxycodone and paraceta-
mol (Table 2). Some drugs were always classified as off-label including clonidine, oxycodone,
midazolam and parecoxib (Table 2). Drugs commonly unlicensed included dexamethasone
and chlorhexidine.
The highest frequency of off-label prescribing occurred in neonates, although there were no
significant differences in the profile of licensed, off-label and unlicensed drugs between age
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groups (p = 0.39) (Table 3). The most commonly prescribed off-label drugs for each age group
were as follows (figures quoted are number and percentages of the off-label drugs administered
within each age group: Table 3);
• Neonates—amoxicillin (n = 3; 37.5%) and nystatin (n = 2; 25.0%)
• Infants—fentanyl (n = 17; 14.7%), ondansetron (n = 14; 12.1%) and paracetamol (n = 10;
8.6%)
• Children—ondansetron (n = 86; 21.2%), fentanyl (n = 50; 12.4%) and oxycodone (n = 40;
9.9%)
• Adolescents—ondansetron (n = 16; 16.5%), fentanyl (n = 13; 13.4%) and oxycodone (n = 10;
10.3%)
No unlicensed drugs were prescribed for neonates. The three unlicensed drugs prescribed
to infants were chlorhexidine (n = 1), diazoxide (n = 1) and phenylephrine (n = 1). The 15





Dosage—High 120 (19.2) Reformulation 7 (38.9)
Dosage—Low 74 (11.8) Extemporaneous preparation 10 (55.6)
Indication 371 (59.3) SAS drug 1 (5.6)
Age 253 (40.4)
Route of administration 39 (6.2)
https://doi.org/10.1371/journal.pone.0210237.t001







Paracetamol 171 38 (22.2) 0.0
Ondansetron 134 116 (86.6) 0.0
Fentanyl 94 81 (86.2) 0.0
Ibuprofen 90 3 (3.3) 0.0
Emla (lignocaine/ prilocaine) 58 1 (1.7) 0.0
Oxycodone 55 55 (100.0) 0.0
Cephazolin 38 14 (36.8) 0.0
Morphine 34 14 (41.2) 0.0
Dexamethasone 31 29 (93.6) 2 (6.5)
Clonidine 21 21 (100) 0.0
Amoxicillin 19 13 (68.4) 0.0
Timentin (ticarcillin/ clavulanic acid) 18 14 (77.8) 0.0
Atracurium 15 6 (40.0) 0.0
Flucloxacillin 15 10 (66.7) 0.0
Gentamicin 15 4 (26.7) 0.0
Parecoxib 13 13 (100.0) 0.0
Salbutamol 13 11 (84.6) 0.0
Chlorhexidine 11 2 (18.2) 8 (72.7)
Midazolam 11 11 (100.0) 0.0
Painstop Day (paracetamol/ codeine phosphate) 11 9 (81.8) 0.0
https://doi.org/10.1371/journal.pone.0210237.t002
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unlicensed drugs prescribed to children included: chlorhexidine (n = 7; 46.7%) and dexameth-
asone or omeprazole in equal numbers (n = 2; 13.3%).
Overall, while 53.9% of all drugs were classified as off-label, the Fisher’s Exact test showed
that off-label and unlicensed rates were strongly associated with the route of administration
(p<0.0001). Notably, the prescribing of topical products was much higher for both the licensed
and unlicensed categories as shown in Table 4.
According to the ATC classification, drugs most commonly prescribed overall were for the
nervous system, the alimentary tract and metabolism and also anti-infectives (Table 5). Off-
label drugs were most often those used for the alimentary tract and metabolism, respiratory
system, blood and blood forming organs and sex hormone preparations (Table 5). Unlicensed
drugs were most often those used for the cardiovascular system and sensory organs (Table 5).
Table 6 shows the number and percentage of patients who were prescribed at least one of
the drugs licensed, off-label or unlicensed. For all drug groups, the 15 patients who received an
unlicensed drug also received one or more licensed drugs as well as at least one off-label drug.
Of the remaining patients, 138 received both a licensed and an off-label drug. There were 35
patients whose charts showed that they received an off-label anti-infective as well as a licensed
one.
Of the 190 patients, when the diagnosis was classified into the World Health Organisation
(WHO) Major Diagnostic Categories (MDCs), the six most common categories were injury,
poisoning and certain other consequences of external causes (n = 33; 17.4%), diseases of the
digestive system (n = 31; 16.3%), symptoms, signs and abnormal clinical and laboratory find-
ings, not elsewhere classified (n = 22; 11.6%), neoplasms (n = 14; 7.4%), congenital malforma-
tions, deformities and chromosomal abnormalities (n = 14; 7.4%) and diseases of the
genitourinary system (n = 13; 6.8%). The number of licensed, off-label and unlicensed drugs
prescribed within the six categories is summarised in Table 7. When considering only licensed
and off-label drugs prescribed within the six most common MDCs, the proportion of licensed
Table 3. Frequency of off label and unlicensed prescribing within each EMEA age classification group, as well as total number of prescriptions per age group. P





Total number of prescriptions P value
Neonate
(Zero- 27days)
8 (66.7) 0 (0.0) 12 0.3922
Infant
(28 days- 23 months)
116 (50.7) 3 (1.3) 229
Children
(2–11 years)
405 (54.5) 15 (2.0) 743
Adolescents
(12–18 years)
97 (55.1) 0 (0.0) 176
https://doi.org/10.1371/journal.pone.0210237.t003








Oral 253 (51.8) 228 (46.7) 7 (1.4) < 0.0001
Injectable 187 (36.5) 324 (63.3) 1 (0.2)
Topical 72 (75.8) 13 (13.7) 10 (10.5)
Inhaled 4 (6.3) 60 (93.8) 0 (0.0)
https://doi.org/10.1371/journal.pone.0210237.t004
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and off-label medications do not appear to differ significantly between diagnostic categories
(p = 0.1605)
Discussion
This study has found that more than half of the drugs prescribed were off-label or unlicensed,
mainly being off-label (54.0%). This was higher than the 25.7% reported by Czarniak et al.
(2015) [1] and another recent Australian study in Tasmania which reported 31.8% [2]. The
most common reason for off-label prescribing in this study was indication (59.3%), whereas
the aforementioned Australian studies both found that high doses were the most common fac-
tor [1, 2]. The current findings show little reduction in the level of off-label prescribing, despite
attempts by regulatory agents to reduce it. Such prescribing lacks scientific evidence and regu-
latory authority. It poses greater risks to patients and a potential for litigation of prescribers
[17]. Variations in study design makes a direct comparison between many studies difficult.
For example, some studies are retrospective [2, 18, 19], while others are prospective [4, 5, 20–
25], in many studies data were collected on all patients admitted to the study ward in a specific
time frame over several weeks [22, 24], while in others data were collected on a specific day
each month for 12 months [25] or one day each week [20] for a specified time. In another
study, medications prescribed to a randomly chosen sample of patients were studied over a 24
hour period [23]. The lengths of studies, the settings and the ages of patients also varied with
studies [4, 19, 22].
With respect to the current study, this was compared to an initial study which was carried
out five years earlier (in 2008) in the same hospital investigating off-label and unlicensed pre-
scribing in inpatients, outpatients and the Emergency Department. A high level of off-label
Table 5. Frequency of off label and unlicensed prescribing for each ATC class, and as a percentage of overall prescribing for each ATC class (n = 1160).
ATC Class








Alimentary tract and metabolism (n = 225; 19.4%) 163 (72.4) 10 (4.4) 52 (19.4)
Blood and blood forming organs (n = 4; 0.3%) 3 (75.0) 0 (0.0) 1 (25.0)
Cardiovascular system (n = 8; 0.7%) 2 (25.0) 2 (25) 4 (50.0)
Dermatologicals (n = 7; 0.6%) 2 (28.6) 1 (14.3) 4 (57.1)
Genitourinary system and sex hormones (n = 2; 0.2%) 2 (100.0) 0 (0.0) 0 (0.0)
Systemic hormonal preparations, excluding sex hormones and insulins (n = 41; 3.5%) 33 (80.5) 2 (4.9) 6 (14.6)
Anti-infectives (n = 195; 16.8%) 112 (57.4) 0 (0.0) 83 (42.6)
Antineoplastic and immunomodulating agents (n = 9; 0.8%) 6 (66.7) 0 (0.0) 3 (33.3)
Musculoskeletal (n = 30; 2.6%) 11 (36.7) 1 (3.3) 18(60.0)
Nervous system (n = 608; 52.4%) 273 (44.9) 0 (0.0) 335 (55.1)
Antiparasitic products, insecticides and repellants (n = 1; 0.1%) 0 (0.0) 0 (0.0) 1 (100.0)
Respiratory system (n = 21; 1.8%) 17 (80.9) 0 (0.0) 4 (19.05)
Sensory organs (n = 7; 0.6%) 1 (14.3) 2 (28.6) 4 (57.1)
Various (n = 2; 0.2%) 1 (50.0) 0 (0.0) 1 (50.0)
https://doi.org/10.1371/journal.pone.0210237.t005
Table 6. Number (percentage) of patients who received at least one of the drugs in the given groups.
Drug group Licensed Off-label Unlicensed None
Any drug 178 (93.7) 165 (86.8) 15 (7.9) 0
Anti-infectives 58 (30.5) 69 (36.3) 0 98 (51.6)
https://doi.org/10.1371/journal.pone.0210237.t006
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prescribing was reported across the three settings (25.7%) however, when only inpatients were
considered, the level of off-label and unlicensed prescribing was 74.4%. Despite a decrease in
off-label and unlicensed prescribing reported in the current study (54.0%), this level is still too
high.
The four most frequently prescribed drugs overall were paracetamol, ondansetron, fentanyl
and ibuprofen. The most commonly prescribed off-label drugs respectively were ondansetron,
fentanyl, oxycodone and paracetamol. Oxycodone, clonidine, parecoxib, and midazolam were
always prescribed off-label. Czarniak et al (2015)[1] also reported that ondansetron was the
most commonly prescribed off-label drug.
Ondansetron was prescribed off-label on 116 occasions, often for reasons of indication
(n = 66; 56.9%) or dose (n = 50; 43.1%). The intravenous formulation (IV) of ondansetron is
indicated for the prevention of post-operative nausea and vomiting (PONV) in children aged
two to 12 years and the IV or oral formulations are both indicated for emetogenic chemother-
apy induced nausea and vomiting in children aged four years and over. Ondansetron was clas-
sified as off-label in children receiving chemotherapy because the dose was calculated based on
0.1mg/kg, rather than 5mg/m2, as specified in the PI. For PONV, it was often prescribed on a
“when required” basis despite the lack of studies evaluating repeat dosing in paediatric patients
experiencing PONV [14]. In multiple instances, children were prescribed oral ondansetron for
PONV, despite the indications in the PI for emetogenic chemotherapy and radiotherapy only.
Similar issues were identified by Ballard et al. (2013)[2].
Paracetamol was often prescribed at doses above the 15mg/kg dose specified in the PI. This
was previously reported by Czarniak et al (2015)[1] and Ballard et al. (2013)[2]. Standard refer-
ence texts used by many clinicians and pharmacists within Australia, but not the PI, state that
paracetamol may be given in doses up to 90mg/kg/day under medical supervision [26, 27],
which was the case for all patients in the study. The legal issues surrounding these findings are
untested.
Off-label prescribing of antibiotics in paediatrics is common and often warranted, however
it is also concerning due to the increase in global antimicrobial resistance [28, 29]. In this
study, five antibiotics, cephazolin, amoxicillin, Timentin (ticarcillin and clavulanic acid), flu-
cloxacillin, and gentamicin, were included in the top 20 most frequently prescribed drugs.
Cephazolin and Timentin were most frequently off-label due to indication, being only indi-
cated in proven infections, and not for prophylactic or empirical use [14]. Amoxicillin and flu-
cloxacillin were mostly classified as off-label because higher doses than recommended in the
PI were prescribed. Similarly to the findings reported by Ballard et al. (2013)[2], gentamicin
was often classified as off-label due to single daily dosing, despite the PI stating that divided
daily doses should be administered [2, 14]. It has been common medical practice for some
Table 7. Frequency of licensed, off-label and unlicensed drugs prescribed to paediatric patients in the six most common WHO major diagnostic categories.
Major Diagnostic Category Licensed Off-label Unlicensed
n % n % n %
2 Neoplasms (n = 94) 30 31.9 61 64.9 3 3.2
11 Diseases of the digestive system (n = 284) 121 42.6 156 54.9 7 2.5
14 Diseases of the genitourinary system (n = 89) 45 50.6 44 49.4 0 0
17 Congenital malformations, deformities and chromosomal abnormalities (n = 98) 49 50 49 50 0 0
18 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (n - = 80) 33 41.3 47 58.8 0 0
19 Injury, poisoning and certain other consequences of external causes (n = 195) 88 45.1 105 53.9 2 1
All others (n = 316) 149 47.2 161 51 6 1.9
https://doi.org/10.1371/journal.pone.0210237.t007
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time to administer gentamicin once daily due to fewer instances of ototoxicity and nephrotoxi-
city [30]. Further, in Australia the AMH [26] and the Paediatric Formulary published by the
Royal Children’s Hospital in Melbourne [31] recommend once daily dosing. It would appear
the PI has not been updated by the sponsor, or any update lacks adequate scientific rigour.
Unlicensed prescribing did not represent a large proportion of prescribing in this study. It
consisted of chlorhexidine (the most commonly prescribed unlicensed drug) and several sus-
pension formulations including allopurinol, dexamethasone, hydrochlorothiazide, omeprazole
and pantoprazole, which were reformulated from tablets into suspensions. Several commer-
cially unavailable eye drops such as phenylephrine eye drops were also prepared extemporane-
ously. This arises because of a lack of suitable paediatric formulations.
Although many drugs have been used in an off-label or unlicensed manner for years, there
seems to be an unwillingness of drug companies to carry out studies in children to expand
their PI’s. Some amendments might be possible based on already published studies subsequent
to initial TGA registration. However, for this to occur, the drug company would need to apply
to the TGA to update the approved information [2]. Unfortunately, there is little incentive for
the drug companies to do this as they will get very little return, notably because children repre-
sent a small proportion of the medicine market. Ethical reasons also limit the number of paedi-
atric clinical trials available, as well as lack of parental awareness of their importance [6, 8].
There were several limitations to this study, including that the data were collected some
years ago and that new medicines and also new patterns of use of old medicines, could have
changed the panorama today. Further, the data were collected retrospectively so there may
have been some omissions in data or the data in the medical records may have been recorded
incorrectly. In addition, it is possible that there may have been errors in collecting the data
although every effort was made to ensure accuracy of data collection. Further, the study was
carried out over a one week period and there is a possibility that it may not reflect prescribing
in another period or season. The study also did not include neonates. This was because PMH
is not a neonatal hospital and only admits children once they have been discharged from a
neonatal hospital or if they require intensive care, which was not part of this study. Regardless,
from this study and others, it is clear that paediatric prescribing needs to become more evi-
dence based and that the evidence available currently needs to be reflected in published prod-
uct information and dosage guidelines. Australia has been attempting to improve research in
paediatric medicine and improve children’s access to medicines, supporting Australia’s Qual-
ity Use of Medicines (QUM) [32]. Although a Paediatric Medicines Advisory Group was
formed in Australia and recently, the (AMH) Children’s Dosing Companion [33], which is
updated annually, has become available, more should be done to improve the quality of evi-
dence for prescribing off-label and unlicensed drugs in children. The AMH Children’s Dosing
Companion [33], which is a useful drug and information reference, is intended to assist practi-
tioners prescribing for children. However, it contains a disclaimer which clearly states that it is
not for sale outside Australia, that information may not be consistent with approved PIs, that
the authors do not warrant the accuracy of the information contained in the AMH Children’s
Dosing Companion and that no responsibility is taken for any loss, damage or injury caused
by using the information therein. The efforts of the EMA and FDA are not yet influencing off-
label and unlicensed prescription numbers in Australia. These data show even higher levels
than others only recently reported. The use of expert groups providing guidance does not
affect the PI decisions and partly circumvents the underlying issue. What is also concerning is
that despite the high level of off-label prescribing for children, neither the current study or the
previous recent Australian studies [1, 2] reported signed consent forms for their use.
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Studies by drug companies are needed to evaluate the safety, quality and efficacy of many
off-label drugs used in paediatrics. Where unlicensed drugs are reformulated in hospitals,
these should be appropriately evaluated by a government sponsored group.
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